23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts

December 19, 2023

https://www.globenewswire.com/news-release/2023/12/19/2798489/0/en/23andMe-announces-further-expansion-of-23ME-00610-Phase-1-2a-clinical-trial-in-advanced-neuroendocrine-and-ovarian-cancer-patient-cohorts.html

Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational antibody targeting CD200R1

Read more at globenewswire.com

Related news for (ME)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.